U.S. Markets closed

Genomic Health reports positive results from Oncotype DX study

Genomic Health announced that The Oncologist published positive results from an Oncotype DX colon cancer decision impact study, demonstrating that Recurrence Score results changed treatment recommendations in 45% of stage II colon cancer patients. This prospective study evaluated 141 stage II colon cancer patients from 17 sites in the Mayo Clinic Cancer Research Consortium. Treatment intensity decreased for 33 percent of patients and increased for more than 11% of patients. Overall, physician recommendations for chemotherapy decreased by 22%.